Polatuzumab Vedotin (DCDS4501A, RG7596) Clinical Trials

TrialTitleStudy Record DetailPhaseSponsor/Colaborator
A Study of DCDS4501A in Combination With Rituximab, Cyclophosphamide, Doxorubicin and Prednisone in Patients With B-Cell Non-Hodgkin’s LymphomaNCT01992653Phase IIGenentech Inc./Roche, F. Hoffmann-La Roche Ltd.
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkins LymphomaNCT01290549Phase IGenentech Inc./Roche, F. Hoffmann-La Roche Ltd.
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan and Evaluation of Combination DCDS4501A and Obinutuzumab in Patients With Non-Hodgkin’s LymphomaNCT01691898Phase IIGenentech Inc./Roche, F. Hoffmann-La Roche Ltd.
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell LymphomaNCT02257567Phase IIGenentech Inc./Roche, F. Hoffmann-La Roche Ltd.

Last Editorial Review: July 15, 2016